BPC-157
Stable gastric pentadecapeptide investigated for tissue repair, angiogenesis and gut protection in predominantly preclinical models.
Explore calculators for this peptide
Use the Peptide Research Tools to experiment with reconstitution, mg/kg ranges and simplified half-life curves for BPC-157. All values are placeholders and must be aligned with your own research protocol.
Open BPC-157 in calculators →
Research frame & potential applications
BPC-157 is a 15–amino acid peptide originally isolated from gastric juice and studied as a pro‑healing, angiogenesis‑modulating compound in a wide range of preclinical models.
Animal and mechanistic work report accelerated repair of tendon, ligament, muscle, bone and gut tissue, often alongside improved microvascular integrity and reduced lesion size, while robust randomized human data remain limited.
Research areas & putative benefits
How BPC‑157 is being explored in the literature – framed as mechanistic and preclinical signals, not treatment claims.
- Acceleration of tendon, ligament and muscle healing in rodent transection, rupture and crush models, with improved biomechanical strength and earlier functional recovery.
- Promotion of angiogenesis and microvascular repair in injured tissues, with denser capillary networks and better perfusion in hypovascular regions.
- Protection of gastric mucosa and gut barrier function in ulcer, colitis and NSAID‑injury models, with smaller lesions and less inflammatory damage.
- Exploratory effects in neural and spinal cord injury models, where improved vascularization and pro‑survival signaling have been reported.
Mechanism stack
Selected pathways proposed to underlie BPC‑157’s pro‑healing and angiogenic actions in preclinical work.
Angiogenesis
VEGF / NO / ERK1/2 axis
BPC‑157 has been reported to enhance VEGF signaling, activate ERK1/2 and endothelial nitric oxide synthase, and increase nitric oxide output, collectively supporting endothelial migration, proliferation and new vessel formation in injured tissue.
Tendon biology
GH receptor & FAK-paxillin
In tendon fibroblasts, BPC‑157 appears to up‑regulate growth hormone receptor expression and modulate FAK‑paxillin signaling, pathways linked to cell adhesion, migration and extracellular matrix remodeling during tendon repair.
Cytoprotection
Pro-survival cascades
Mechanistic studies describe increased AKT activation and early changes in transcription factors such as c‑Fos, c‑Jun and EGR‑1, consistent with enhanced cell survival, stress adaptation and regenerative gene expression.
Gastroprotection
Mucosal barrier & inflammation
In GI models, BPC‑157 supports re‑epithelialization, maintains tight‑junction integrity and dampens damaging inflammatory cascades, which together help preserve mucosal barrier function under chemical or mechanical stress.
Evidence snapshot
Representative findings from tendon, angiogenesis and detection work relevant to BPC‑157 research.
| Model / context | Observation | Notes |
|---|---|---|
|
Tendon fibroblasts (in vitro)
Cellular (tendon)
|
BPC‑157 increased growth hormone receptor expression and altered FAK‑paxillin gene expression in tendon cells, alongside changes consistent with enhanced migration and matrix interaction. | Provides a mechanistic basis for improved biomechanical healing seen in tendon injury models. |
|
Tendon & muscle injury in rodents
Preclinical musculoskeletal
|
Treatment accelerated structural repair and functional recovery, with more organized collagen fibers and denser vascular networks at the injury site compared with controls. | Effects have been reported across Achilles tendon, muscle crush and ligament injury paradigms. |
|
Gastrointestinal injury models
Preclinical GI
|
BPC‑157 reduced lesion size and improved mucosal integrity in gastric ulcer, colitis and NSAID‑induced injury models, often with lower local inflammatory markers. | Supports its framing as a “stable gastric pentadecapeptide” with systemic repair signals. |
|
Detection & elimination
Analytical / doping
|
Modern LC‑MS methods have detected BPC‑157 and metabolites in urine several days after administration, with low nanogram‑per‑milliliter detection thresholds. | Relevant for anti‑doping considerations and for planning sampling windows in research protocols. |
Risk frame & unknowns
Key limitations and open questions to keep in mind when interpreting BPC‑157 data.
Important research caveats
- Evidence base is dominated by preclinical and mechanistic work; high‑quality randomized human outcome trials are sparse.
- Long‑term safety, off‑target effects and optimal dosing in humans are not well characterized, especially for chronic or systemic use.
- Preparation quality, purity and dosing can vary substantially between research suppliers, complicating comparisons across studies.
- Regulatory status differs by region, and use outside controlled research environments raises questions around oversight, interactions and misuse.
This dossier summarizes mechanistic and preclinical findings on BPC‑157 for scientific and educational purposes only.
It does not provide medical advice, treatment guidance or dosing recommendations.